The company reported positive interim safety and biomarker data from its lead drug candidate PMN310, including zero ARIA-E cases across all patient genotypes, favorable overall safety profile, and early biomarker movement consistent with target engagement. These results support the company's mechanism of selectively targeting toxic oligomers while avoiding ARIA risks, positioning the drug favorably ahead of full 12-month results in Q1 2027.
Company reported meaningful clinical progress with first human evidence of target engagement by lead drug candidate PMN310, demonstrating dose-dependent oligomer reduction in CSF. Positive Phase 1a results, FDA Fast Track Designation, and upcoming Phase 1b interim data support advancement toward later-stage trials. The selective oligomer-targeting mechanism may offer safety advantages over existing plaque-binding antibodies.
Articles that tag PMN but are mainly about other companies.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
